6 stories

Biogen Idec Inc. is targeting a yet-untreated disease that affects 150,000 Americans while seeking to expand its business of producing drugs for neurological disorders through a deal with a young Cambridge startup.

Cambridge-based Biogen today said it has backed Ataxion, a startup founded a year ago by Cambridge venture capital firm Atlas Venture. Both Biogen and Atlas took part in a $17 million funding deal for the startup, which could also see Ataxion acquired by Biogen if certain milestones are achieved.More →